Creo Medical Group plc
("Creo" the "Company" or the "Group")
Change of Nominated Adviser and Joint Broker
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that following the completion of the all share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Joint Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.
Enquiries:
| Creo Medical Group plc | |
| Richard Rees (CFO) | +44 (0)1291 606 005 |
| | |
| Cavendish Capital Markets Limited | +44 (0)20 7397 8900 |
| Stephen Keys / Camilla Hume (NOMAD) | |
| Michael Johnson (Sales) | |
| | |
| Numis Securities Limited (Joint Broker) | +44 (0)20 7260 1000 |
| Freddie Barnfield / Duncan Monteith / Euan Brown | |
| | |
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
| Paul McManus / Sam Allen Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7867 984 082 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
